We also demonstrated the molecular mechanism by which the mTOR inhibitor rapamycin arrests the aberrant epithelial proliferation in the ADPKD kidney, which resulted de novo from PC2 dysfunction. This evidence concerns the gene PKD2 and autosomal dominant polycystic kidney disease.